Asparaginase untuk Terapi Leukemia Limfoblastik Akut pada Anak
Analisis
DOI:
https://doi.org/10.55175/cdk.v52i3.1379Kata Kunci:
Asparaginase, keganasan pada anak, leukemia limfoblastik akutAbstrak
Leukemia limfoblastik akut (acute lymphoblastic leukemia/ALL) merupakan keganasan yang paling sering didiagnosis pada anak. Five-year survival rate di negara berpenghasilan tinggi lebih baik dibandingkan negara berpenghasilan rendah. Asparaginase masih merupakan salah satu obat yang penting dalam terapi ALL pada anak. Terdapat beberapa tipe asparaginase yang beredar di seluruh dunia, seperti asparaginase E. coli, pegasparaginase, asparaginase Erwinia, calaspargase pegol, dan asparaginase Erwinia rekombinan. Reaksi hipersensitivitas merupakan komplikasi utama terkait asparaginase. Hal yang juga menjadi concern adalah antibodi anti-asparaginase yang menyebabkan silent inactivation, sehingga terapi tidak bermanfaat. Pemantauan terapeutik perlu dilakukan pada pasien ALL anak yang menjalani terapi asparaginase.
Unduhan
Referensi
Maese L, Rau RE. Current use of asparaginase in acute lymphoblastic leukemia/lymphoblastic lymphoma. Front Pediatr. 2022;10:902117. DOI: 10.3389/fped.2022.902117
Inaba H, Pui CH. Advances in the diagnosis and treatment of prediatric acute lymphoblastic leukemia. J Clin Med. 2021;10:1926. DOI: 10.3390/jcm10091926.
Malczewska M, Kosmider K, Bednarz K, Ostapinska K, Lejman M, Zawitkowska J. Recent advances in treatment options for childhood acute lymphoblastic leukemia. Cancers 2022;14:2021. DOI: 10.3390/cancers14082021.
Perdana AB, Saputra F, Aisyi M. Update on diagnosis of childhood acute lymphoblastic leukemia (ALL) in Indonesia. Indon J Cancer 2020;14(4):115-6. DOI: 10.33371/ijoc.v14i4.818
Garniasih D, Susanah S, Sribudiani Y, Hilmanto D. The incidence and mortality of childhood acute lymphoblastic leukemia in Indonesia: A systematic review and meta-analysis. PLoS ONE 2022;17(6):e0269706. DOI: 10.1371/journal.pone.0269706.
Kato M, Manabe A. Treatment and biology of pediatric acute lymphoblastic leukemia. Pediatr Internat 2018;60:4-12. DOI: 10.1111/ped.13457.
Ekpa QL, Akahara PC, Anderson AM, Adekoya OO, Ajayi OO, Alabi PO, et al. A review of acute lymphocytic leukemia (ALL) in the pediatric population: Evaluation current trends and changes in guidelines in the past decade. Cureus 2023;15(12):e49930. DOI: 10.7759/cureus.49930.
Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. Haematologica 2020;105(11):2524-39. DOI: 10.3324/haematol.2020.247031.
Hayashi H, Makimoto A, Yuza Y. Treatment of pediatric acute lymphoblastic leukemia: A historical perspective. Cancers 2024;16:273. DOI: 10.3390/cancers16040723.
Pieters R, Hunger SP, Boos J, Rizzari C, Silverman L, Baruchel A, et al. L-asparaginase treatment in acute lymphoblastic leukemia. A focus on Erwinia asparaginase. Cancer 2011;117:238-49. DOI: 10.1002/cncr.25489.
Cecconello DK, de Magalhaes MR, Werlang ICR, de Martino Lee ML, Michalowski MB, Daudt LE. Asparaginase: An old drug with new questions. Hematol Transfus Cell Ther. 2020;42(3):275-82. DOI: 10.1016/j.htct.2019.07.010.
Hill JM, Roberts J, Loeb E, Khan A, MacLellan A, Hill RW. L-asparaginase therapy for leukemia and other malignant neoplasms. N Engl J Med. 1967;202(9):882-8. DOI: 10.1001/jama.1967.03130220070012.
Radadiya A, Zhu W, Coricello A, Alcaro S, Richards NGJ. Improving the treatment of acute lymphoblastic leukemia. Biochemistry 2020;59:3193-200. DOI: 10.1021/acs.biochem.0c00354.
Egler RA, Ahuja SP, Matloub Y. L-asparaginase in the treatment of patients with acute lymphoblastic leukemia. J Pharmacol Pharmacother. 2016;7:62-71. DOI: 10.4103/0976-500X.184769.
Asparaginase. Product Information. FDA [Internet]. 2013 [cited 2024 Jun 25]. Available from: www.fda.gov
Bender C, Maese L, Carter-Febres M, Verma A. Clinical utility of pegaspargase in children, adolescents and young adult patients with acute lymphoblastic leukemia: A review. Blood and Lymphatic Cancer: Targets and Therapy 2021;11:25-40. DOI: 10.2147/BLCTT.S245210.
Rau RE, Dreyer ZA, Choi MR, Liang W, Skowronski R, Allamneni KP, et al. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children’s Oncology Group. Pediatr Blood Cancer 2018. DOI: 10.1002/pbc.26873.
Hijiya N, van der Sluis I. Asparaginase-associated toxicity in children with acute lymphoblastic leukemia. Leukemia & Lymphoma 2016;57(4):748-57. DOI: 10.3109/10428194.2015.1101098.
Pegasparaginase. Product Information. FDA [Internet]. 2024 [cited 2024 Jun 25]. Available from: www.fda.gov
Dai ZJ, Huang YQ, Lu Y. Efficacy and safety of PEG-asparaginase versus E. coli L-asparaginase in Chinese children with acute lymphoblastic leukemia: A meta-analysis. Transl Pediatr. 2021;10(2):244-55. DOI: 10.21037/tp-20-178.
Asparaginase Erwinia chrysanthemi. Product Information. FDA [Internet]. 2011 [cited 2024 Jun 25]. Available from: www.fda.gov
Salzer W, Seibel N, Smith M. Erwinia asparaginase in pediatric acute lymphoblastic leukemia. Expert Opin Biol Ther. 2012;12(10):1407-14. DOI: 10.1517/14712598.2012.718327.
Vrooman LM, Supko JG, Neuberg DS, Asselin BL, Athale UH, Clavell L, et al. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2010;54:199-205. DOI: 10.1002/pbc.22225.
Vrooman LM, Blonquist TM, Stevenson KE, Supko JG, Hunt SK, Cronholm SM, et al. Efficacy and toxicity of pegasparagase and calaspargase pegol in childhood acute lymphoblastic leukemia: Results of DFCI 11-001. J Clin Oncol. 2021;39:3496-505. DOI: 10.1200/JCO.20.03692.
Maese L, Loh ML, Choi MR, Lin T, Aoki E, Zanette M, et al. Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: Results from the phase 2/3 AALL1931 study. Blood 2023;141(7):704-12. DOI: 10.1182/blood.2022016923.
Maese L, Rizzari C, Coleman R, Power A, van der Sluis I, Rau RE. Can recombinant technology address asparaginase Erwinia chrysanthemi shortages? Pediatr Blood Cancer 2021;68:e29169. DOI: 10.1002/pbc.29169.
Lin T, Hernandez-Illas M, Rey A, Jenkins J, Chandula R, Silverman JA, et al. A randomized phase I study to evaluate the safety, tolerability, and pharmacokinetics of recombinant Erwinia asparaginase (JZP-458) in healthy volunteers. Clin Transl Sci. 2021;14(3):870-9. DOI: 10.1111/cts.12947.
Maese L, Loh MN, Choi MR, Lin T, Aoki E, Zanette M, Agarwal S, et al. Recombinant Erwinia asparaginase (JPZ458) in acute lymphoblastic leukemia: Results from the phase 2/3 AALL1931 study. Blood 2023;141(7):704-12. DOI: 10.1182/blood.2022016923.
Maese L, Loh MN, Choi MR, Lin T, Aoki E, Agarwal S, et al. Efficacy and safety of recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL): Complete follow-up of the Children’s Oncology Group (COG) AALL1931 study. Blood 2023;142(suppl 1):1498. DOI: 10.1182/blood-2023-172577.
Sandley M, Angus J. Asparaginase therapy in patients with acute lymphoblastic leukemia: Expert opinion on use and toxicity management. Leukemia & Lymphoma 2023;64(4):776-87. DOI: 10.1080/10428194.2023.2171267.
Burke MJ, Zalewska-Szewczyk B. Hypersensitivity reactions to asparaginase therapy in acute lymphoblastic leukemia: Immunology and clinical consequences. Future Oncol. 2022;18(10):1285-99. DOI: 10.2217/fon-2021-1288.
Huynh VT, Bergeron S. Asparaginase toxicities: Identification and management in patients with acute lymphoblastic leukemia. Clin J Oncol Nurs. 2017;21(5):E248-59. DOI: 10.1188/17.CJON.E248-E259.
Unduhan
Diterbitkan
Cara Mengutip
Terbitan
Bagian
Lisensi
Hak Cipta (c) 2025 Hastarita Lawrenti
Artikel ini berlisensi Creative Commons Attribution-NonCommercial 4.0 International License.
